How Does Medicaid Managed Care Address the Needs of Beneficiaries with Opioid Use Disorders? A Deep Dive into Contract Design
Many people who experience opioid use disorder rely on Medicaid. The high penetration of managed care systems into Medicaid raises the importance of understanding states' expectations regarding coverage, access to care, and health system performance and effectively elevates agreements between states and plans into blueprints for coverage and care. Federal law broadly regulates these structured agreements while leaving a high degree of discretion to states and plans. In this study, researchers reviewed the provisions of 15 state Medicaid managed care contract related to substance use disorder (SUD) treatment to identify whether certain elements of SUD treatment were a stated expectation and the extent to which the details of those expectations varied across states in ways that ultimately could affect evaluation of performance and health outcomes. We found that while all states include SUD treatment as a stated contract expectation, discussions around coverage of specific services and nationally recognized guidelines varied. These variations reflect key state choices regarding how much deference to afford their plans in coverage design and plan administration and reveal important differences in purchasing expectations that could carry implications for efforts to examine similarities and differences in access, quality, and health outcomes within managed care across the states.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
American journal of law & medicine - 49(2023), 2-3 vom: 01. Juli, Seite 339-348 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morris, Rebecca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1017/amj.2023.35 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368349381 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368349381 | ||
| 003 | DE-627 | ||
| 005 | 20240214233347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/amj.2023.35 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368349381 | ||
| 035 | |a (NLM)38344786 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morris, Rebecca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How Does Medicaid Managed Care Address the Needs of Beneficiaries with Opioid Use Disorders? A Deep Dive into Contract Design |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Many people who experience opioid use disorder rely on Medicaid. The high penetration of managed care systems into Medicaid raises the importance of understanding states' expectations regarding coverage, access to care, and health system performance and effectively elevates agreements between states and plans into blueprints for coverage and care. Federal law broadly regulates these structured agreements while leaving a high degree of discretion to states and plans. In this study, researchers reviewed the provisions of 15 state Medicaid managed care contract related to substance use disorder (SUD) treatment to identify whether certain elements of SUD treatment were a stated expectation and the extent to which the details of those expectations varied across states in ways that ultimately could affect evaluation of performance and health outcomes. We found that while all states include SUD treatment as a stated contract expectation, discussions around coverage of specific services and nationally recognized guidelines varied. These variations reflect key state choices regarding how much deference to afford their plans in coverage design and plan administration and reveal important differences in purchasing expectations that could carry implications for efforts to examine similarities and differences in access, quality, and health outcomes within managed care across the states | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Medicaid | |
| 650 | 4 | |a coverage | |
| 650 | 4 | |a insurance | |
| 650 | 4 | |a substance use | |
| 700 | 1 | |a Rosenbaum, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Grogan, Colleen |e verfasserin |4 aut | |
| 700 | 1 | |a Rhodes, Meredith |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Christina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of law & medicine |d 1977 |g 49(2023), 2-3 vom: 01. Juli, Seite 339-348 |w (DE-627)NLM001599011 |x 0098-8588 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:2-3 |g day:01 |g month:07 |g pages:339-348 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/amj.2023.35 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 2-3 |b 01 |c 07 |h 339-348 | ||